This study reveals that the proinflammatory chemokine CXCL14 activates MAS-related G protein-coupled receptor MRGPRX2; these results provide a rational basis for the future development of idiopathic pulmonary fibrosis therapies. Here, CXCL14 is linked to idiopathic pulmonary fibrosis.